In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Corcept Therapeutics Incorporated. Trade Record

NASDAQ:CORT Corcept Therapeutics Incorporated stock gains 18.51% Exit Sep 21, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart CORT Aug 28, 2017, priceSeries
About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with Cushing's syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
94.33
Entry Date
Aug 28, 2017
Entry Price
14.69
Sell Date
Sep 21, 2017
Sell Price
17.41
Net Gain
18.51%
Hold Time
17 Trading Days